Accessibility Menu
Hst Global logo

Hst Global(OTC) HSTC

Market Cap$99.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year+637%
1 Year+174,900%
1 Month+0%
$0.70
+0%
+0.00Today
Hst Global last closing stock price
MetricPriceDate
Last closeUSD 0.702026-07-23
Hst Global stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.702026-07-15
1 month+0%USD 0.702026-06-18
3 month+12%USD 0.632026-04-22
Year to date-29.29%USD 0.992025-12-26
1 year+174,900%USD 0.002025-07-22
3 year+309.36%USD 0.172023-07-24
5 year+636.84%USD 0.102021-07-23
Since inception-99.59%USD 172.502008-05-12

Hst Global Financials at a Glance

Market Cap

$99.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$767.94K

Net Income (TTM)

-$442.68K

EPS (TTM)

-$0.00

P/E Ratio

-162.79

Dividend

$0.00

Beta (Volatility)

12.61 (High)

Price

$0.70

Volume

400

Open

$0.70

Previous Close

$0.70

Daily Range

$0.70 - $0.70

52-Week Range

$0.00 - $1.05

Estimated Earnings Date

Jul 6, 2026

HSTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hst Global

HST Global, Inc. operates as a biotechnology firm dedicated to integrated health and wellness. The company establishes and acquires a global network of specialized wellness centers, offering homeopathic and alternative treatments primarily for patients suffering from advanced-stage cancers.

Products and Services
  • Specialized wellness centers for alternative cancer treatments
  • Development of homeopathic therapeutic candidates
  • Focus on late-stage cancer and critical condition therapies
Growth Outlook
  • Recent revenue of $154,240 shows potential for growth
  • Gross profit margin improved to 74% in Q1 2026
  • Expansion plans for wellness centers in new markets
Financial Highlights
  • Net income for Q1 2026 was -$107,889, indicating ongoing challenges
  • Current ratio of 0.66 suggests liquidity concerns
  • Market capitalization stands at approximately $29.5 million
HST Global, Inc. is positioned in the biotechnology sector, focusing on innovative health solutions. The company’s commitment to developing alternative treatments for advanced-stage cancers reflects a growing trend in personalized medicine. Despite facing financial challenges, recent revenue figures and improvements in gross profit margins indicate potential for future growth. The expansion of wellness centers could further enhance market presence and revenue streams. Investors may find interest in the company's unique approach to healthcare and its focus on addressing critical health issues.
AI Generated • Jul 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Michael P. Fortkort

Website

www.hstglobal.com

Headquarters

Hampton, VA 23666, US

HSTC Financials

Key Financial Metrics (TTM)

Gross Margin

79.41%

Operating Margin

-45.88%

Net Income Margin

-57.64%

Return on Equity

-3.64%

Return on Capital

-6.09%

Return on Assets

-3.33%

Earnings Yield

-0.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$99.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

141.43M

Volume

400

Avg. Volume

99.21

Financials (TTM)

Gross Profit

$609.86K

Operating Income

-$352.31K

EBITDA

-$194.22K

Operating Cash Flow

-$1.49M

Capital Expenditure

-$11.00

Free Cash Flow

-$1.49M

Cash & ST Invst.

$20.62K

Total Debt

$928.68K

Hst Global Performance Analysis

Hst Global annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 523,980N/A
Hst Global sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31108.4%
Q12026-03-31-44.0%
Q22026-06-3033.6%
Hst Global annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.03-2.5%
20232023-12-31USD -0.031.1%
20242024-12-31USD -0.00-84.2%
20252025-12-31USD -0.0138.6%
Hst Global sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3014.8%
Q42025-12-3143.5%
Q12026-03-31161.5%
Q22026-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$206.06K

N/A

Gross Profit

$165.98K

+514.1%

Gross Margin

80.55%

N/A

Market Cap

$99.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$99.00M

N/A

Employees

1

N/A

Net Income

$5.64K

+103.6%

EBITDA

$83.58K

+182.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$20.62K

+704.1%

Total Debt

$928.68K

-18.6%

Accounts Receivable

$251.43K

+5880.8%

Inventory

$393.36K

N/A

Long Term Debt

$211.32K

-58.1%

Short Term Debt

$717.36K

+12.8%

Return on Assets

-3.33%

N/A

Return on Invested Capital

-2.83%

N/A

Free Cash Flow

-$33.92K

+59.2%

Operating Cash Flow

-$33.92K

+59.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONPHOncology Pharma Inc.
$0.05+0.00%
STABStatera Biopharma, Inc.
$0.00+0.00%
TRVNTrevena, Inc.
$0.01+0.00%
INFIQInfinity Pharmaceuticals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About HSTC

What is the current price of Hst Global?

Hst Global is trading at $0.70 per share.

What is the 52-week range for Hst Global?

Over the past 52 weeks, Hst Global has traded between $0.00 and $1.05.

How much debt does Hst Global have?

As of the most recent reporting period, Hst Global reported total debt of $928.68K.

How much cash does Hst Global have on hand?

Hst Global reported $20.62K in cash and cash equivalents in its most recent financial results.

What is Hst Global’s dividend yield?

Hst Global does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services